137 related articles for article (PubMed ID: 12798640)
21. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
[TBL] [Abstract][Full Text] [Related]
22. Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection.
van Diepen A; Brand HK; de Waal L; Bijl M; Jong VL; Kuiken T; van Amerongen G; van den Ham HJ; Eijkemans MJ; Osterhaus AD; Hermans PW; Andeweg AC
J Virol; 2015 May; 89(9):5022-31. PubMed ID: 25694607
[TBL] [Abstract][Full Text] [Related]
23. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine.
Klinguer-Hamour C; Libon C; Plotnicky-Gilquin H; Bussat MC; Revy L; Nguyen T; Bonnefoy JY; Corvaïa N; Beck A
Vaccine; 2002 Jun; 20(21-22):2743-51. PubMed ID: 12034101
[TBL] [Abstract][Full Text] [Related]
24. Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination.
Helson R; Olszewska W; Singh M; Megede JZ; Melero JA; O'Hagan D; Openshaw PJ
Vaccine; 2008 Feb; 26(6):753-61. PubMed ID: 18191308
[TBL] [Abstract][Full Text] [Related]
25. Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.
O'Konek JJ; Makidon PE; Landers JJ; Cao Z; Malinczak CA; Pannu J; Sun J; Bitko V; Ciotti S; Hamouda T; Wojcinski ZW; Lukacs NW; Fattom A; Baker JR
Hum Vaccin Immunother; 2015; 11(12):2904-12. PubMed ID: 26307915
[TBL] [Abstract][Full Text] [Related]
26. DNA vaccine encoding central conserved region of G protein induces Th1 predominant immune response and protection from RSV infection in mice.
Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zheng YP; Hong T; He JS
Immunol Lett; 2016 Nov; 179():95-101. PubMed ID: 27688078
[TBL] [Abstract][Full Text] [Related]
27. Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.
Lee YN; Hwang HS; Kim MC; Lee YT; Lee JS; Moore ML; Kang SM
Antiviral Res; 2015 Mar; 115():1-8. PubMed ID: 25513755
[TBL] [Abstract][Full Text] [Related]
28. Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.
Boyoglu-Barnum S; Chirkova T; Todd SO; Barnum TR; Gaston KA; Jorquera P; Haynes LM; Tripp RA; Moore ML; Anderson LJ
J Virol; 2014 Sep; 88(18):10569-83. PubMed ID: 24990999
[TBL] [Abstract][Full Text] [Related]
29. Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection.
Harker JA; Lee DC; Yamaguchi Y; Wang B; Bukreyev A; Collins PL; Tregoning JS; Openshaw PJ
J Virol; 2010 May; 84(10):5294-302. PubMed ID: 20200251
[TBL] [Abstract][Full Text] [Related]
30. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
[TBL] [Abstract][Full Text] [Related]
31. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
32. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
[TBL] [Abstract][Full Text] [Related]
33. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
[TBL] [Abstract][Full Text] [Related]
34. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection.
Cautivo KM; Bueno SM; Cortes CM; Wozniak A; Riedel CA; Kalergis AM
J Immunol; 2010 Dec; 185(12):7633-45. PubMed ID: 21084664
[TBL] [Abstract][Full Text] [Related]
35. Targeting CD40 enhances antibody- and CD8-mediated protection against respiratory syncytial virus infection.
Muralidharan A; Russell M; Larocque L; Gravel C; Li C; Chen W; Cyr T; Lavoie JR; Farnsworth A; Rosu-Myles M; Wang L; Li X
Sci Rep; 2018 Nov; 8(1):16648. PubMed ID: 30413743
[TBL] [Abstract][Full Text] [Related]
36. Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice.
Bian C; Liu S; Liu N; Zhang G; Xing L; Song Y; Duan Y; Gu H; Zhou Y; Zhang P; Li Z; Zhang K; Wang Z; Zhang S; Wang X; Yang P
Antiviral Res; 2014 Apr; 104():110-7. PubMed ID: 24509239
[TBL] [Abstract][Full Text] [Related]
37. Gene expression differences in lungs of mice during secondary immune responses to respiratory syncytial virus infection.
Schuurhof A; Bont L; Pennings JL; Hodemaekers HM; Wester PW; Buisman A; de Rond LC; Widjojoatmodjo MN; Luytjes W; Kimpen JL; Janssen R
J Virol; 2010 Sep; 84(18):9584-94. PubMed ID: 20592085
[TBL] [Abstract][Full Text] [Related]
38. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV).
Hancock GE; Heers KM; Smith JD; Scheuer CA; Ibraghimov AR; Pryharski KS
Vaccine; 2001 Sep; 19(32):4874-82. PubMed ID: 11535341
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of STAT6 during vaccination with formalin-inactivated RSV prevents induction of Th2-cell-biased airway disease.
Srinivasa BT; Fixman ED; Ward BJ
Eur J Immunol; 2014 Aug; 44(8):2349-59. PubMed ID: 24796717
[TBL] [Abstract][Full Text] [Related]
40. Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.
Lee Y; Lee YT; Ko EJ; Kim KH; Hwang HS; Park S; Kwon YM; Kang SM
Hum Vaccin Immunother; 2017 Nov; 13(11):2594-2605. PubMed ID: 28854003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
